Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial

International Journal of Cardiology

Volumn 167, Issue 4, 2013, Pages 1632-1637

  Mrdovic, Igor ^a,b   Savic, Lidija ^b   Krljanac, Gordana ^b   Asanin, Milika ^a,b   Perunicic, Jovan ^a,b   Antonijevic, Nebojsa ^a,b   Lasica, Ratko ^b   Marinkovic, Jelena ^a,c   Kocev, Nikola ^a,c   Vasiljevic, Zorana ^a,b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c Institute for Medical Statistics and Informatics   (Serbia)

Author keywords

Aggregation; Antiplatelet therapy; Primary PCI

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; TICLOPIDINE; TIROFIBAN;

ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; TREATMENT DURATION;

AGGREGATION; ANTIPLATELET THERAPY; PRIMARY PCI;

AGED; ASPIRIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; SINGLE-BLIND METHOD; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84881480800     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.04.129     Document Type: Article

References (29)

1. T.F. Althoff, M. Fischer, E. Langer, S. Ziemer, and G. Baumann Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients Thromb Res 125 5 2010 e190 e196
2. G. Campo, M. Valgimigli, and D. Gemmati Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention. Insights into the STRATEGY study J Am Coll Cardiol 48 2006 2178 2185
3. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
4. R. Marcucci, A.M. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. A 12-month follow-up Circulation 119 2009 237 242
5. S. Matetzky, B. Shenkman, and V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
6. K.P. Bliden, J. DiChiara, U.S. Tantry, A.K. Bassi, S.K. Chaganti, and P.A. Gurbel Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 49 2007 657 666
7. G. Parodi, R. Marcucci, and R. Valenti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
8. P.G. Buonamici, R. Marcucci, and A. Migliorini Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 24 2007 2312 2317
9. D. Sibbing, S. Braun, and T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
10. P. Wenaweser, J. Dörffler-Melly, and K. Imboden Stent thrombosis is associated with an impaired response to antiplatelet therapy J Am Coll Cardiol 45 2005 1748 1752
11. B. Aleil, L. Jacquemin, and F. De Poli Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: Results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study JACC Cardiovasc Interv 1 2008 631 638
12. N. Von Beckerath, A. Kastrati, and A. Wieczorek A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur Heart J 28 2007 1814 1819
13. S. Matetzky, P. Fefer, B. Shenkman, D. Varon, N. Savion, and H. Hod Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction Am J Cardiol 102 2008 524 529
14. M.J. Price, P.B. Berger, and P.S. Teirstein Standard- versus high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. The GRAVITAS Randomized Trial JAMA 305 2011 1097 1105
15. The CURRENT-PCI OASIS 7 investigators Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
16. A. Calatzis, A. Giebl, C. Jambor, and M. Spannagl Clopidogrel responsiveness and TRAP-6 induced aggregometry: a study in patients on chronic anti-platelet treatment Haemostaseologie 1 2009 A63
17. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
18. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
19. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
20. D. Sibbing, S. Schulz, and S. Braun Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement J Thromb Haemost 8 2010 250 256
21. G. Yong, J. Rankin, and L. Ferguson Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: Results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) trial Am Heart J 157 2009 60.e1 60.e9
22. J.M. Siller-Matulaa, K. Haberla, K. Prillingera, S. Panzerb, I. Langc, and B. Jilma The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation Thromb Res 123 2009 874 880
23. Z. Motovska, P. Widimsky, and R. Petr Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness Int J Cardiol 144 2010 255 257
24. U.S. Tantry, K.P. Bliden, and P.A. Gurbel What is the best measure of thrombotic risks - pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation? Catheter Cardiovasc Interv 66 2005 597 598
25. R. Paniccia, E. Antonucci, and N. Maggini Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy Am J Clin Pathol 131 2009 834 842
26. A. Ballemain-Appaix, D. Brieger, and F. Beygui New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention. A meta-analysis J Am Coll Cardiol 56 2010 1542 1551
27. S.S. Jolly, J. Pogue, and K. Haladyn Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study Eur Heart J 30 2009 900 907
28. D.L. Bhatt, J. Scheiman, and N.S. Abraham ACCF/ACG/AHA 2008 Expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents Circulation 118 2008 1894 1909
29. I. Mrdovic, L. Savic, and G. Krljanac Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI score Int J Cardiol 162 3 2013 220 227